» Articles » PMID: 35922937

The Fibrosis-4 Index Predicts Cardiovascular Prognosis in Patients With Severe Isolated Tricuspid Regurgitation

Overview
Journal Circ J
Date 2022 Aug 4
PMID 35922937
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The fibrosis-4 (FIB-4) index is used to evaluate liver disease patients. It can also be used to evaluate the prognosis for heart disease patients; however, its ability to determine the prognosis of severe isolated tricuspid regurgitation (TR) patients is unclear. This study aimed to clarify the association between FIB-4 index scores and the cardiovascular prognosis for severe isolated TR patients.

Methods and results: This was a dual-center, retrospective study. From 2011 to 2019, 111 consecutive outpatients with severe isolated TR (mean age, 68.6 years; 53.2% male) were evaluated. Major adverse cardiovascular events (MACEs) were defined as the composite of cardiovascular death, hospitalization for heart failure, myocardial infarction, and stroke. The association between FIB-4 index scores and echocardiography was also evaluated. During a median follow up of 3.0 years, 24 patients were lost to follow up and 40 MACEs occurred. Baseline FIB-4 index scores for patients with MACEs were significantly higher than those for patients without MACEs. A multivariate analysis revealed that FIB-4 index scores are significantly associated with MACEs (hazard ratio, 1.89; 95% confidence interval, 1.01-3.54; P=0.046). A linear regression analysis indicated that FIB-4 index scores were correlated with echocardiographic parameters, including the left atrial volume index and left ventricular end-diastolic diameter.

Conclusions: The FIB-4 index score may be a useful predictor of MACEs for patients with severe isolated TR.

Citing Articles

Fibrosis-4 index is closely associated with future development of hypertension in the Japanese general population.

Yamashita S, Takase H, Kawakatsu N, Hayashi K, Kin F, Isogaki T Hypertens Res. 2024; 48(2):796-804.

PMID: 39639128 DOI: 10.1038/s41440-024-02028-4.


Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes.

Cernea S, Onisor D, Roiban A, Benedek T, Rat N World J Cardiol. 2024; 16(10):580-594.

PMID: 39492975 PMC: 11525805. DOI: 10.4330/wjc.v16.i10.580.


A Novel Liver Fibrosis Marker FIB-5 Index Predicted Response to Cardiac Resynchronization Therapy and Prognostic Outcomes in Patients With Heart Failure.

Iwawaki T, Inden Y, Yanagisawa S, Goto T, Kondo S, Tachi M Ann Noninvasive Electrocardiol. 2024; 29(5):e70004.

PMID: 39101582 PMC: 11299164. DOI: 10.1111/anec.70004.


Association of liver fibrosis-4 index with adverse outcomes in hypertrophic cardiomyopathy patients.

Abdu F, Mareai R, Xiang L, Galip J, Mohammed A, Zhang W ESC Heart Fail. 2024; 11(6):3934-3945.

PMID: 39049566 PMC: 11631238. DOI: 10.1002/ehf2.14977.


Clinical value of the fibrosis-4 index in predicting mortality in patients with right ventricular pacing.

Inoue N, Morikawa S, Ogane T, Hiramatsu T, Murohara T PLoS One. 2024; 19(2):e0294221.

PMID: 38315703 PMC: 10843135. DOI: 10.1371/journal.pone.0294221.